Triple Negative Breast Cancer — PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
Citation(s)
A Pilot Study of Neoadjuvant Response-Adapted Chemotherapy With Pembrolizumab in Patients With Stage 2 and 3 Triple Negative Breast Cancer to Determine Early PET and Biomarker Dynamics